XTX Topco’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-10,053
Closed -$290 3397
2025
Q1
$290 Sell
10,053
-71,407
-88% -$12K ﹤0.01% 2329
2024
Q4
$18.7K Buy
81,460
+52,626
+183% +$63.2K ﹤0.01% 2053
2024
Q3
$62K Buy
+28,834
New +$104K ﹤0.01% 1665
2024
Q2
Sell
-10,949
Closed -$58.6K 2587
2024
Q1
$58.6K Sell
10,949
-57
-0.5% -$394 0.01% 1448
2023
Q4
$85.7K Buy
+11,006
New +$37.7K 0.02% 1146
2022
Q2
Sell
-4,456
Closed -$53K 1157
2022
Q1
$53K Buy
4,456
+3,304
+287% +$59.1K 0.02% 586
2021
Q4
$38K Buy
+1,152
New +$46.6K 0.02% 591
2021
Q3
Sell
-2,602
Closed -$142K 1126
2021
Q2
$142K Buy
2,602
+1,485
+133% +$87.9K 0.05% 613
2021
Q1
$84K Buy
+1,117
New +$116K 0.04% 580

XTX Topco's SYRS Position: Q2 2025 in Review

XTX Topco sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2025, closing a stake of 10,053 shares — an estimated $290 sold.

XTX Topco first reported a position in SYRS in Q1 2021 and held it in 9 quarters. The position peaked at $142K in Q2 2021. 0 funds tracked by Wall St. Rank hold SYRS as of Q2 2025.

  • XTX Topco reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
  • XTX Topco sold 10,053 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2025, an estimated $290.
  • XTX Topco first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
  • XTX Topco's Syros Pharmaceuticals, Inc. Common Stock position peaked at $142K in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2025.

Based on XTX Topco's 13F filing for Q2 2025, filed 12 Aug 2025.